Test Price
2,800 AED✅ Home Collection Available
AMPD2 Gene SPG63 Hereditary Spastic Paraplegia NGS Test in UAE | 2800 AED
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO‑accredited Next‑Generation Sequencing in our UAE‑licensed facility.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Complimentary Telephonic Post‑Test Clinical Guidance to interpret results and coordinate with your neurologist.
- Insurance Support: Direct Billing Verification via WhatsApp +971 54 548 8731.
Key Metrics
- Test Price: 2,800 AED
- Turnaround Time: 3‑4 weeks with comprehensive clinical report
- Sample Type: Peripheral whole blood or extracted DNA
- Methodology: Next‑Generation Sequencing (NGS) with full gene coverage
Test Overview & Methodology
The AMPD2 SPG63 Genetic Test uses next‑generation sequencing to detect pathogenic variants in the AMPD2 gene, confirming hereditary spastic paraplegia type 63 (SPG63) – a rare neurological disorder affecting corticospinal tract function. This comprehensive assay reads the entire coding region, intron‑exon boundaries, and selected regulatory elements to identify point mutations, small insertions/deletions, and copy number variations. Results are returned within 3‑4 weeks with full clinical interpretation, including variant classification per ACMG guidelines and disease‑specific management recommendations.
| Parameter | Our NGS AMPD2 Test | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Precision | Full gene coverage, detects point mutations, deletions/duplications, and novel variants | Limited to known mutation hot‑spots only |
| Method | Next‑Generation Sequencing (NGS) with bioinformatic verification | Sanger sequencing of selected exons |
| Speed | 3‑4 weeks with comprehensive report | 6‑8 weeks, often requires reflex testing |
| Diagnostic Yield | ~85‑90% for SPG63 phenotype | <50% due to limited coverage |
Physician Insight & Safety Protocols
“Hereditary spastic paraplegia type 63 due to AMPD2 mutations requires a multidisciplinary approach combining genetic confirmation, neurological examination, and family history assessment. Our NGS assay delivers comprehensive coverage of the AMPD2 gene, enabling precise molecular diagnosis. Always correlate genetic findings with clinical presentation and pursue genetic counselling for at‑risk family members.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication Advisory
Do not discontinue, adjust, or initiate any prescribed neurological medication without direct consultation with your treating physician. This genetic test provides diagnostic information and does not replace ongoing clinical management or emergency care.
Exclusion Criteria & Emergency Red Flags
Exclusion Criteria
- Inability to provide informed consent as per Federal Decree‑Law No. 4 of 2016 on Medical Liability and UAE genetic testing regulations.
- Patient without a clinical indication for genetic testing, as determined by a neurologist or clinical geneticist.
- Recent (within 3 months) allogeneic bone marrow transplant or blood transfusion that may interfere with DNA analysis.
Red Flags – Seek Immediate Care
- Rapidly progressing leg weakness or spasticity with loss of ambulation before receiving results.
- Development of seizures, sudden vision loss, or severe cognitive decline.
- Any acute neurological emergency – proceed to the nearest hospital; do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the AMPD2 SPG63 genetic test and why is it important?
The AMPD2 SPG63 NGS test identifies disease‑causing mutations in the AMPD2 gene to confirm hereditary spastic paraplegia type 63, enabling early intervention and tailored management. This rare neurodegenerative condition affects walking and coordination; a precise genetic diagnosis helps guide physical therapy, medication choices, and family planning. Our test uses next‑generation sequencing to read the entire coding region, offering the highest diagnostic yield available in the UAE.
2. How is the test performed and what sample is required?
A simple blood draw (peripheral whole blood in EDTA tube) or extracted DNA sample is collected by our licensed phlebotomist during a scheduled home visit. The VIP mobile phlebotomy service operates daily from 8 AM to 11 PM across Dubai and all emirates. Once received at our ISO‑certified laboratory, DNA is extracted, libraries are prepared, and sequencing is performed on an Illumina platform. A mandatory pre‑test genetic counselling session documents family history and obtains informed consent as required by UAE law.
3. What do my results mean and what follow‑up is required?
A positive report indicates a confirmed genetic diagnosis of SPG63; your neurologist will discuss prognosis, symptomatic management, and family screening recommendations. Variants are classified using ACMG/AMP guidelines. Negative results may still require further investigation if clinical suspicion remains high. We provide a complimentary post‑test tele‑consultation with our genetics team to explain findings and coordinate care with your treating physician.
4. Is genetic counselling included with this test?
Yes. Pre‑test and post‑test genetic counselling is an integral part of our service and is included in the test price. Our Consultant Medical Genetics, Lina Osama Zaki Quteineh, or a certified genetic counsellor will guide you through the implications of testing, discuss potential outcomes, and support family communication. This ensures informed decision‑making and compliance with UAE regulatory standards for genetic testing.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
DNA Labs UAE operates in full compliance with the following UAE federal laws and regulatory standards applicable to genetic testing and patient data handling:
- Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing the collection, processing, storage, and transfer of personal health data.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating health information systems, telemedicine, and electronic health records.
- Federal Decree‑Law No. 4 of 2016 on Medical Liability – establishing legal frameworks for medical practice, patient consent, and clinical accountability.
- Dubai Healthcare City (DHCC) Regulatory Standards – ensuring compliance with local licensing, quality assurance, and ethical research guidelines.
All genetic data is encrypted, access‑controlled, and stored within UAE‑based servers. Results are shared only with the requesting physician and the patient through secure channels.
Clinical & Logistical Metadata
| Test Name | AMPD2 Gene Sequencing – Hereditary Spastic Paraplegia Type 63 (SPG63) NGS Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3‑4 weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA) or extracted genomic DNA |
| Methodology Used | Next‑Generation Sequencing (NGS) – Illumina platform, full gene coding region coverage + exon‑intron boundaries |
| ICD-10-CM Code | G11.4 |
| LOINC Code | 95035-9 |
| DHA Facility License & Laboratory Address | DHA Facility License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians